Mallinckrodt and Daiichi in nuclear medicine deal:
This article was originally published in Clinica
Executive Summary
Mallinckrodt has appointed Daiichi Radioisotope Laboratories exclusive distributor for some of its radiopharmaceuticals in Japan. Mallinckrodt will have exclusive distribution rights to some of Daiichi's products outside Japan. Mallinckrodt says that demand for nuclear medicine is growing in Japan. In a separate development, Mallinckrodt has announced the resignation of Raymond Lark, executive vice-president and CEO of its respiratory products unit. The unit was previously Nellcor Puritan Bennett which was acquired in August.